ENVI's concession for clinical investigations of short-term high-risk devices
This article was originally published in Clinica
When the European Parliament’s lead committee voted on the compromise amendments to the European Commission’s proposed medical devices Regulation on 25 September, there were few changes to the articles that most concern industry when compared with the same articles in the 13 September proposed compromise amendments that had been put forward by ENVI rapporteur Dagmar Roth Behrendt.
You may also be interested in...
While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?
Updated medtech notified body figures from the European Commission always make headline news. But industry needs to see real appointments now, not a list of tricky-to-understand numbers.
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.